In the Eye of the Storm: PD-(L)1 Inhibitors Weathering Turbulence
Over the past decade, PD-1/PD-L1 checkpoint inhibitors have transformed the oncology treatment landscape. Its commercial promise has resulted in an increasingly crowded marketplace, with over 5,600 clinical trials in the works.
Discover how you can navigate the complexities of the future immunotherapy landscape as a PD-1/PD-L1 player, with insights from Scrip, presented in partnership with IQVIA.
Download your free white paper to explore:
- Competitive dynamics in the PD-1/PD-L1 market
- Emerging innovation landscape for PD-1/PD-L1 inhibitors
- Future outlook: Considerations for innovators